Proteomics

Dataset Information

0

An Anticancer Rhenium Tricarbonyl Targets Fe-S Biogenesis in Ovarian Cancer Cells – Profiling


ABSTRACT: Target identification remains a critical challenge in inorganic drug discovery to deconvolute potential polypharmacology. Here, we describe an improved approach to prioritize candidate protein targets based on a combination of dose-dependent chemoproteomics and treatment effects in living cancer cells for the rhenium tricarbonyl compound TRIP. Chemoproteomics revealed 89 dose-dependent targets with competing concentrations between 0.1–32 µM despite the broad proteotoxic effects of TRIP. Target response networks revealed two highly probable targets of which the Fe-S cluster biogenesis factor NUBP2 was competed by free TRIP at nanomolar concentrations. Importantly, TRIP treatment led to a down-regulation of Fe-S cluster-containing proteins and upregulated ferritin. Fe-S cluster depletion was further verified by assessing mitochondrial bioenergetics. Consequently, TRIP emerges as a first-in-class modulator of the scaffold protein NUBP2, which disturbs Fe-S cluster biogenesis at sub-cytotoxic concentrations in ovarian cancer cells.

INSTRUMENT(S): timsTOF Pro

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Epithelial Ovarian Cancer Cell

SUBMITTER: Christopher Gerner  

LAB HEAD: Christopher Gerner

PROVIDER: PXD034472 | Pride | 2025-04-22

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20-Prot-1275_GA1_1_2091.d.rar Other
20-Prot-1276_GA2_1_2092.d.rar Other
20-Prot-1277_GA3_1_2093.d.rar Other
20-Prot-1278_GA4_1_2095.d.rar Other
20-Prot-1279_GA5_1_2096.d.rar Other
Items per page:
1 - 5 of 39

Similar Datasets

2025-04-22 | PXD034466 | Pride
2023-12-27 | PXD045443 | Pride
2024-07-13 | PXD053317 | Pride
2021-10-21 | ST001954 | MetabolomicsWorkbench
2018-07-11 | PXD006928 | Pride
2018-07-11 | PXD006938 | Pride
2021-09-09 | PXD020228 | Pride
2007-12-14 | E-MEXP-1215 | biostudies-arrayexpress
2021-07-15 | GSE154169 | GEO
2020-08-28 | GSE120704 | GEO